MARKET WIREYahoo! Finance Canada • 6h ago
Pyxis Oncology, Inc. (PYXS) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
Why PYXS Stock dropped -4.23% Today — RQD Quant Desk Flash
$1.81 -4.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.79
Pyxis Oncology Inc. (PYXS) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $226.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PYXS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PYXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Pyxis Oncology Inc. (NASDAQ: PYXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.81 (-4.23% 1D, market cap $226.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PYXS ranks #880 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PYXS compare to KROS and SLGL in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PYXS carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 82.8%, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C+ grade (66/100 RQD, P/E N/A, ROIC 85.0%, cap $225.2M) and SLGL (Sol-Gel Technologies Ltd.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -35.0%, cap $224.8M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PYXS?
▼
Per PYXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782223), Pyxis Oncology Inc. generated $13.9M in revenue (-14.2% YoY), -$79.6M in net income, and -$63.5M in free cash flow against $91.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.79 (-0.95%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-13.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PYXS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY PYXS SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (28% of score)
FRED Regime × Technicals: 17% of 52W Range • RSI-14 at 34.8 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$2.01-12.4% Next Q
37
Q2 (-2Q)Grade E$1.76-4% Next Q
34
Q3 (-1Q)Grade E$1.69+7.1% Next Q
32
CurrentGrade E$1.81-9.8% Hist 90D α
29
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PYXS Turnaround Squeeze
While PYXS currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.63) and Max Pain ($1.90) forces dealer call-delta covering toward $5.83.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PYXS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PYXS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PYXS Stock dropped -4.23% Today — RQD Quant Desk Flash
Pyxis Oncology Inc. (PYXS) dropped -4.23% to $1.81, trading at 17% of its 52-week range ($1.03 – $5.55). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 17% of its 52-week range ($1.03 – $5.55) with RSI-14 at 34.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.81 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 82.8% gross margin and $0 annual free cash flow.
Live PYXS Headlines & Catalysts
CATALYSTSeeking Alpha • 9h ago
Pyxis Oncology: Better Runway Is Bullish For MICVO’s Remaining R&D (NASDAQ:PYXS)Seeking Alpha report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStockInvest.us • 12h ago
Pyxis Oncology Stock Price Forecast. Should You Buy PYXS?StockInvest.us report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 15h ago
Price to book forward of Pyxis Oncology, Inc. – NASDAQ:PYXSTradingView report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 18h ago
One cancer drug spans three presentations, from lab tests to patient studyStock Titan report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 21h ago
Pyxis Oncology stock: Wells Fargo keeps USD 19.00 target for PYXS stockad-hoc-news.de report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsYahoo Finance report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSeeking Alpha • 1d ago
Pyxis: Downgrading To 'Hold' After PYX-106 Dropped And Continued HNSCC Advancement MICVOSeeking Alpha report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 5d ago
Pyxis Oncology to Participate in Upcoming Investor ConferencesBOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Chief Execut
MARKET WIREBenzinga • 6d ago
Pyxis Oncology To Present Late-Breaking Oral Data On MICVO Monotherapy In Previously Treated Recurrent/Metastatic Head And Neck Cancer At EORTC-NCI-AACR SymposiumPyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO)
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PYXS)
- ✓Walkthrough of PYXS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PYXS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.84%🛡️ HOLDING TREND SUPPORT
2026-11-02O $1.83H $1.86L $1.68C $1.81VOL 427.9K
RES: $4.99SUP: $1.60SMA50: $2.63SMA200: $2.16
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PYXS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -14.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PYXS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PYXS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PYXS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PYXS)
Health Care Rank #880 of 1016
⚔️ KROS vs PYXS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PYXS vs. KROS, SLGL, SIGA, BBOT)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Pyxis Oncology Inc. (PYXS) ranks #880 by composite RQD confidence (29/100, grade E) and #560 by equity capitalization ($226.0M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with PYXS at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PYXS
ACTIVE
Pyxis Oncology Inc. | E | 29/100 | — | 82.8% | -35.0% | -4.23% | $226.0M | Benchmark Subject |
| KROS Keros Therapeutics Inc. | C+ | 66/100 | — | — | 85.0% | -2.82% | $225.2M | /kros-vs-pyxs → |
| SLGL Sol-Gel Technologies Ltd. | D+ | 54/100 | — | — | -35.0% | -0.45% | $224.8M | /slgl-vs-pyxs → |
| SIGA SIGA Technologies Inc. | B | 72/100 | 9.8x | 68.6% | 42.7% | -4.40% | $228.5M | /siga-vs-pyxs → |
| BBOT BridgeBio Oncology Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -2.96% | $216.5M | /bbot-vs-pyxs → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001782223In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pyxis Oncology Inc. (PYXS) reported GAAP revenue of $13.9M (-14.2% vs. FY2024 revenue of $16.1M ) , GAAP net income of -$79.6M, operating cash flow of -$63.5M, and free cash flow of -$63.5M (-9.7% YoY). On the balance sheet, PYXS closed FY2025 with $91.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $13.9M | -$79.6M | -$63.5M | -$63.5M | $91.5M | — |
| FY2024 (FY) | 2024-12-31 | $16.1M | -$77.3M | -$57.7M | -$57.9M | $157.2M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$73.8M | -$70.7M | -$70.7M | — | — |
3. PYXS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PYXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Pyxis Oncology Inc. (NASDAQ: PYXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.81 (-4.23% 1D, market cap $226.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PYXS ranks #880 in composite RQD confidence.
How does PYXS compare to KROS and SLGL in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PYXS carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 82.8%, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C+ grade (66/100 RQD, P/E N/A, ROIC 85.0%, cap $225.2M) and SLGL (Sol-Gel Technologies Ltd.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -35.0%, cap $224.8M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PYXS?
Per PYXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782223), Pyxis Oncology Inc. generated $13.9M in revenue (-14.2% YoY), -$79.6M in net income, and -$63.5M in free cash flow against $91.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PYXS trading relative to its 50-day, 200-day, and 52-week technical levels?
PYXS last traded at $1.81 (-4.23% on volume of 686,540 shares), positioning the stock -31.18% below its 50-day simple moving average ($2.63) and -16.20% below its 200-day simple moving average ($2.16). Across its 52-week range of $1.03 to $5.55, PYXS sits at the 17.3% percentile with a 14-day RSI of 34.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.58 to $2.04).
PYXS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PYXS stock moving today?
Why PYXS Stock dropped -4.23% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 29/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
PYXS — Pyxis Oncology Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:40:35Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, PYXS scores 29 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars break down as follows. Fundamental cash engine scores 6/20, reflecting ROIC of -35% and an FCF yield of 0%. Whale 13F flow scores 4/20, covering institutional accumulation and options positioning. Insider conviction scores 3/20, based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 8/20, with a beta of 1.0 and sector sensitivity noted. Forensic balance sheet scores 8/20, citing an Altman Z of 2.5, a Piotroski F of 3/9, and a Debt/Equity of 0.5.
For a prospective investor evaluating the stock today, the rating points to weak cash generation and low scores across ownership-signal pillars. The fundamental pillar is the most direct caution: negative ROIC and zero FCF yield indicate the business is not currently converting capital into owner cash returns. The insider and whale pillars score lowest, which the rating reads as limited conviction from insiders and institutions in the source data. The balance-sheet pillar is middling rather than distressed, so solvency is a less acute concern than operating losses. Upside drivers, if any, would have to come from changes in the cash engine or in ownership conviction, neither of which the rating currently shows. Valuation cannot be assessed on earnings multiples because P/E and EV/EBITDA are not available in source data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $13.9M | $-84.4M | $-79.6M | N/A | $-63.5M | $15.4M | N/A |
| FY 2024 | $16.1M | $-89.5M | $-77.3M | N/A | $-57.9M | $19.5M | N/A |
| FY 2023 | $0.0M | $-82.2M | $-73.8M | N/A | $-70.7M | N/A | N/A |
Per the SEC financials, operating losses and negative free cash flow appear in each reported period, and revenue declined from $16.1M in FY 2024 to $13.9M in FY 2025. Per the market data, ROIC is -35% and the operating margin is -60%. The Roarable RQD rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity of 0.5. Cash is reported for FY 2025 and FY 2024, and debt is not available in source data for any period.
Recent Catalysts & News Wire Analysis
The news feed contains six items, all tagged to PYXS, from sources including Yahoo! Finance Canada, Seeking Alpha, StockInvest.us, TradingView, Stock Titan, and ad-hoc-news.de. Headlines cover general market and institutional coverage, a Seeking Alpha piece titled around a better runway for remaining R&D, a Stock Titan item on a cancer drug spanning three presentations, and an ad-hoc-news.de item referencing a Wells Fargo price target of USD 19.00. The Seeking Alpha item is classified as a CATALYST and carries a GREEN light; the remaining items are classified as market wire and carry YELLOW lights. The Wells Fargo target is listed in the headline but is not corroborated by the analyst section. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so there are no graph-derived catalysts.
Open Questions
- What are the company's products, pipeline stage, and revenue sources, given that the profile and business description lack detail?
- What explains the decline in revenue from FY 2024 to FY 2025, and what is driving the operating losses?
- Why is debt reported as N/A across all periods while the RQD rating cites a Debt/Equity of 0.5?
- What is the cash runway implied by $15.4M in cash against FY 2025 negative FCF of $-63.5M?
- What is the basis for the Wells Fargo USD 19.00 target referenced in the news feed, given that analyst data is absent?
PYXS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Pyxis Oncology Inc. (PYXS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 6h ago
Pyxis Oncology, Inc. (PYXS) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 9h ago
Pyxis Oncology: Better Runway Is Bullish For MICVO’s Remaining R&D (NASDAQ:PYXS) Seeking Alpha report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 12h ago
Pyxis Oncology Stock Price Forecast. Should You Buy PYXS? StockInvest.us report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 15h ago
Price to book forward of Pyxis Oncology, Inc. – NASDAQ:PYXS TradingView report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 18h ago
One cancer drug spans three presentations, from lab tests to patient study Stock Titan report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 21h ago
Pyxis Oncology stock: Wells Fargo keeps USD 19.00 target for PYXS stock ad-hoc-news.de report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Yahoo Finance report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Seeking Alpha • 1d ago
Pyxis: Downgrading To 'Hold' After PYX-106 Dropped And Continued HNSCC Advancement MICVO Seeking Alpha report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PYXS Bull vs. Bear Conversation Board — What's Your Call at $1.81?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PYXS 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.66 (-12.2%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is PYXS (E • RQD 29/100) a Buy at $1.89?
Welcome to the PYXS (Pyxis Oncology Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.42 (-24.9%)
Spot @ $1.89 Pump the brakes on PYXS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on PYXS, but look at what you are paying: current EV/EBITDA multiples with 82.8% gross margins. Unless Pyxis Oncology Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $2.32 (+22.8%)
Spot @ $1.89 PYXS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on PYXS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.89 (52-wk range $1.77 - $2.18), any beat on forward guidance forces shorts and underweight funds to chase.